DeepQure Inc. — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications3liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
HyperQure Renal Denervation SystemHQ-HTN-K01-02 is a prospective, multicenter, single arm, open label, first-in-human study to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic denervation therapy, in patients with resistant hypertension on 3 or more antihypertensive medications	Hypertension	Non applicable	À vérifier	South Korea	À vérifier
HyperQureTM Renal Denervation (RDN) System:HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications	Hypertension	Non applicable	À vérifier	United States	À vérifier
HyperQureTM Renal Denervation (RDN) System:HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications	Hypertension	Non applicable	À vérifier	United States	À vérifier
HyperQure Renal Denervation SystemHQ-HTN-K01-02 is a prospective, multicenter, single arm, open label, first-in-human study to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic denervation therapy, in patients with resistant hypertension on 3 or more antihypertensive medications	Hypertension	Non applicable	À vérifier	South Korea	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
HyperQure Renal Denervation System	Hypertension	Non applicable	NCT06216808	A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension	ACTIVE_NOT_RECRUITING
HyperQureTM Renal Denervation (RDN) System:	Hypertension	Non applicable	NCT06526858	Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension	RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
HyperQure Renal Denervation System		Efficacy and safety of extravascular renal denervation in patients with resistant hypertension: a study protocol for a pilot, single-arm, multi-center, first-in-human study.	Clinical hypertension
HyperQure Renal Denervation System		Long-term outcomes following radiofrequency renal denervation: meta-analysis of 18 reports.	European journal of preventive cardiology
HyperQureTM Renal Denervation (RDN) System:		An expert consensus statement on renal denervation for the management of hypertension endorsed by the Portuguese Association of Interventional Cardiology of the Portuguese Society of Cardiology (APIC-SPC) and the Portuguese Society of Hypertension (SPH).	Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology